中文

← All funding rounds

Orakl Oncology

EuropeDrug discoveryVillejuif, France, FranceFounded 2023Private

Website · orakl-oncology.com ↗

A Gustave Roussy spin-out that grows tumour organoids from real patients, screens them against drugs and links each result to the patient's clinical history and molecular data, to train models that predict how cancer drugs will perform in trials and to find new drug targets.

Disclosed total$34M + €14M≈ $48.7M · in USD at each round's date
Rounds on record3
Latest round$34MSeries A · 2026-11-13
Last stated valuationNone stated
Investors named14
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date2024202520262027≈$3.16M≈$11.6M$34M
Closed round

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-11-13Series A
    Round

    $34M

    For: a larger dataset and AI research team, five times the data generation, lung and gastric cancer beyond colorectal and pancreatic, new US and UK teams to deploy predictions across more than 10 drug programmes, and identifying and validating new drug co-targets

    Data generationModels and platformCommercial roll-out

    Read in InfraVia's release of 13 November on EuropaWire, which quotes the company and both leads and calls the round oversubscribed; the Patient Autonome Fund is managed by Bpifrance. It puts the total raised at $50M and gives no valuation. EU-Startups also covered the round; that page refused automated readers and was not read.

    Co-lead · Norrsken VCCo-lead · SingularInfraVia GrowthSerenaBpifrance Patient Autonome Fundteampact.venturesPlug and PlayThomas WolfStan PoluJacques BoitreaudMostafa El SayedExisting investor · Verve VenturesExisting investor · SpeedinvestExisting investor · HCVC

    On the deal: Agate Freimane (General Partner, Norrsken VC); Jeremy Uzan (Co-founder and General Partner, Singular); Thomas Wolf (Angel investor)

    Announced by the company · news.europawire.eu ↗On the timeline →

  2. 2024-12-03Seed
    Round

    €11M≈ $11.6M

    For: growth and the launch of two commercial products, O-Predict and O-Validate

    Commercial roll-out

    Read on the company counsel's deal page and in Tech.eu's report of 3 December 2024. Both say the round had support from Bpifrance, including the Grand Prix i-Lab, and participation from existing investors, none named.

    Lead · Singular

    Advisers: McDermott Will & Emery (counsel to the company)

    Announced by the company · mcdermottlaw.com ↗

  3. 2023-10Pre-seed
    Round

    €3M≈ $3.16M

    Not stated

    Stated on the company counsel's page for the December 2024 seed; no announcement of the pre-seed itself was read.

    Lead · SpeedinvestHCVCVerve Ventures

    Announced by the company · mcdermottlaw.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.